OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase II clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC).